Hanhart Joel, Rozenman Yaacov
Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel.
Ophthalmologica. 2017;238(1-2):110-118. doi: 10.1159/000473864. Epub 2017 May 24.
To compare the visual and anatomic outcomes of macular edema secondary to retinal vein occlusion after switching from bevacizumab to ranibizumab, aflibercept, or dexamethasone implant.
Fifteen eyes were switched to ranibizumab, 12 to aflibercept, and 10 to dexamethasone. At 3, 6, 9, and 12 months, the outcome measures were visual acuity (VA) and central macular thickness (CMT).
One year after the switch, CMT decreased from 430.11 ± 91.21 to 291.86 ± 43.87 μm (p < 0.001). VA increased in 59.5% of the eyes. No difference between the groups was found in those outcomes at 1 year, but the number of injections varied: 3.30 ± 0.95 for dexamethasone, 6.50 ± 2.11 for aflibercept, and 8.27 ± 2.37 for ranibizumab (p < 0.001).
Most of the eyes that failed initial bevacizumab therapy benefit from switching to another modality. The number of required injections during the first year after the switch varies.
比较视网膜静脉阻塞继发黄斑水肿患者从贝伐单抗转换为雷珠单抗、阿柏西普或地塞米松植入剂后的视力和解剖学结果。
15只眼转换为雷珠单抗，12只眼转换为阿柏西普，10只眼转换为地塞米松。在3、6、9和12个月时，测量指标为视力（VA）和中心黄斑厚度（CMT）。
转换治疗1年后，CMT从430.11±91.21μm降至291.86±43.87μm（p<0.001）。59.5%的患眼视力提高。1年后，各治疗组在这些结果上未发现差异，但注射次数有所不同：地塞米松组为3.30±0.95次，阿柏西普组为6.50±2.11次，雷珠单抗组为8.27±2.37次（p<0.001）。
大多数初始贝伐单抗治疗失败的患眼从转换为其他治疗方式中获益。转换治疗后第一年所需的注射次数有所不同。
